Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Summit Therapeutics
Pharma
Akeso's 34% overall survival win comes with caveats
While ivonescimab and chemo's 34% improvement on overall survival exceeded expectations, detailed data from Harmoni-6 are being picked apart.
Angus Liu
May 31, 2026 8:00am
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
May 27, 2026 11:25am
Summit, UCB-Candid, J&J—Fierce Pharma Asia
May 8, 2026 8:30am
Summit shares tumble on interim PD-1/VEGF trial miss
May 1, 2026 10:56am
J&J alleges trade secret theft by former staffer linked to Summit
Mar 16, 2026 10:44am
AZ, Boehringer-Simcere, Daiichi and more—Fierce Pharma Asia
Jan 30, 2026 7:45am
